Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Effect of colchicine on mortality in patients with COVID-19 – A systematic review and meta-analysis
Zein et al., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2022.102395 (meta analysis)
Zein et al., Effect of colchicine on mortality in patients with COVID-19 – A systematic review and meta-analysis, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2022.102395 (meta analysis)
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Systematic review and meta analysis showing that colchicine was associated with lower mortality in COVID-19 patients:
All studies: RR 0.66 [95%CI 0.53, 0.83], p < 0.001; I2: 42%
RCTs: RR 0.81 [95%CI 0.54, 1.20], p = 0.29; I2: 10%
The RCT result is non-significant, but is highly affected by the very late stage RECOVERY trial, which is not generalizable to earlier usage.
Currently there are 46 colchicine studies and meta analysis shows:
OutcomeImprovement
Mortality35% lower [23‑45%]
Ventilation29% lower [-15‑56%]
ICU admission25% lower [3‑43%]
Hospitalization18% lower [9‑26%]
Cases9% more [-6‑27%]
Zein et al., 12 Jan 2022, peer-reviewed, 2 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Abstract: Journal Pre-proof Effect of colchicine on mortality in patients with COVID-19 – A systematic review and meta-analysis Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello PII: S1871-4021(22)00009-1 DOI: https://doi.org/10.1016/j.dsx.2022.102395 Reference: DSX 102395 To appear in: Diabetes & Metabolic Syndrome: Clinical Research & Reviews Received Date: 8 December 2021 Revised Date: 6 January 2022 Accepted Date: 8 January 2022 Please cite this article as: Zein AFMZ, Raffaello WM, Effect of colchicine on mortality in patients with COVID-19 – A systematic review and meta-analysis, Diabetes & Metabolic Syndrome: Clinical Research & Reviews (2022), doi: https://doi.org/10.1016/j.dsx.2022.102395. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 Published by Elsevier Ltd on behalf of Diabetes India. Title: Effect of Colchicine on mortality in patients with COVID-19 – A systematic review and meta-analysis Short Title: Colchicine and COVID-19 Ahmad Fariz Malvi Zamzam Zein, MD, FINASIM, FACP ORCID ID: 0000-0001-7821-3813 ro of Email: fariz_zein_dr@yahoo.com -p Department of Internal Medicine, Faculty of Medicine, Universitas Swadaya Gunung Jati, re Cirebon, Indonesia na lP Department of Internal Medicine, Waled General Hospital, Cirebon, Indonesia ur Wilson Matthew Raffaello MD Jo ORCID ID: 0000-0002-4086-1492 Email: wilsonkores@gmail.com Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia Corresponding Author: Ahmad Fariz Malvi Zamzam Zein, MD, FINASIM, FACP ORCID ID: 0000-0001-7821-3813 Email: fariz_zein_dr@yahoo.com Department of Internal Medicine, Faculty of Medicine, Universitas Swadaya Gunung Jati, of Cirebon, Indonesia re -p ro Department of Internal Medicine, Waled General Hospital, Cirebon, Indonesia lP Abstracts: 226 words Jo ur na 1662 words Conflict of Interest None Funding of None ro Ethical Approval -p Not Applicable lP re Informed Consent na Not Applicable ur Data Availability Figures: 5 Jo Data are available on reasonable request Table: 1 Contributorship Statement: AFMZZ was involved in the conceptualization and design of the manuscript. AFMZZ and WMR participated in data curation and investigation. AFMZZ performed formal and statistical analysis. AFMZZ and WMR drafted the manuscript. AFMZZ and WMR review and edited the manuscript. Effect of Colchicine on mortality in patients with COVID-19 – A systematic review and metaanalysis Abstract Background and Aim This systematic review and meta-analysis aimed to evaluate the latest evidence on the of association between colchicine and mortality in patients with COVID-19. -p ro Methods re We performed a comprehensive literature search from the PubMed, Scopus, Embase, lP EuropePMC, and Clinicaltrials.gov up until 02 January 2022. We include randomized controlled na trials (RCTs) and observational studies reporting colchicine use in patients with COVID-19 and mortality within 30..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit